4-phenyl-2-propionamidotetraline and Neuralgia

In this study, we investigated whether melatonin treatment prevents development of neuropathic pain via suppression of glial mitogen-activated protein kinases (MAPKs) activation in the cuneate nucleus (CN) in a lysophosphatidylcholine (LPC)-induced median nerve demyelination neuropathy model. Rats were fed orally with melatonin once a day at a dose of 37.5, 75, or 150 mg/kg 30 min before until 3 days after LPC treatment. Subsequently, behavioral tests were conducted on these animals, and immunohistochemistry and immunoblotting were used for qualitative and quantitative analysis of glia and MAPKs, including ERK, JNK, and p38, activation. Enzyme-linked immunosorbent assays were applied to measure pro-inflammatory cytokine responses. Furthermore, intra-CN microinjection of S26131 (MT

Topics: Animals; Demyelinating Diseases; Lysophosphatidylcholines; Male; Melatonin; Microinjections; Neuralgia; Neuroglia; Rats; Rats, Sprague-Dawley; Receptor, Melatonin, MT2; Tetrahydronaphthalenes